Art. -Nr.: HY-144256

CHD1Li 6.11

Name: CHD1Li 6.11
Brand: MedChemExpress
SKU: HY-144256
Price: 280.00 USD
Availability: InStock
Rating: 5 (1 reviews)

Kundenbewertung

Based on 1 Customer Validation

CHD1Li 6.11 is a potent and orally active Chromodomain Helicase DNA Binding Protein 1 Like (CHD1L) (oncogenic gene) inhibitor (IC₅₀ = 3.3 µM for cat-CHD1L recombinant protein). CHD1Li 6.11 can inhibit EMT, induce mesenchymal-epithelial transition (reverse EMT) and promote apoptosis in tumor organoid models. CHD1Li 6.11 can be used for the research of cancer, such as colorectal cancer.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit : 99.54%
CAS. Nr.: 2716890-91-2
Formel: C₂₁H₂₂BrN₅OS
Molecular Weight:472.40

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

CHD1Li 6.11 Chemical Structure

CAS. Nr.: 2716890-91-2

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll (11)
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

Helicase

Alle DNA/RNA Synthesis Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
HCT-116	IC₅₀	0.8 μM Compound: 6.11	Inhibition of cell stemness in human HCT-116 M-phenotype cells assessed as reduction in colony formation Inhibition of cell stemness in human HCT-116 M-phenotype cells assessed as reduction in colony formation	[PMID: 35192363]
HCT-116	IC₅₀	4.3 μM Compound: 6.11	Cytotoxicity against human HCT-116 M-phenotype tumor organoid assessed as reduction in cell viability incubated for 72 hrs by CellTiter Glo assay Cytotoxicity against human HCT-116 M-phenotype tumor organoid assessed as reduction in cell viability incubated for 72 hrs by CellTiter Glo assay	[PMID: 35192363]
HCT-116	IC₅₀	5 μM Compound: 6.11	Induction of mesenchymal-epithelial transition in human HCT-116 M-phenotype tumor organoid assessed as downregulation of vimentin expression by fluorescence analysis Induction of mesenchymal-epithelial transition in human HCT-116 M-phenotype tumor organoid assessed as downregulation of vimentin expression by fluorescence analysis	[PMID: 35192363]
SW-620	IC₅₀	1.6 μM Compound: 6.11	Inhibition of cell stemness in human SW-620 M-phenotype cells assessed as reduction in colony formation Inhibition of cell stemness in human SW-620 M-phenotype cells assessed as reduction in colony formation	[PMID: 35192363]
SW-620	IC₅₀	2.6 μM Compound: 6.11	Cytotoxicity against human SW-620 M-phenotype tumor organoid assessed as reduction in cell viability incubated for 72 hrs by CellTiter Glo assay Cytotoxicity against human SW-620 M-phenotype tumor organoid assessed as reduction in cell viability incubated for 72 hrs by CellTiter Glo assay	[PMID: 35192363]
SW-620	IC₅₀	2.6 μM Compound: 6.11	Cytotoxicity against human SW-620 tumor organoid assessed as reduction in cell viability incubated for 72 hrs by CellTiter Glo assay Cytotoxicity against human SW-620 tumor organoid assessed as reduction in cell viability incubated for 72 hrs by CellTiter Glo assay	[PMID: 35192363]
SW-620	IC₅₀	3.3 μM Compound: 6.11	Induction of mesenchymal-epithelial transition in human SW-620 M-phenotype tumor organoid assessed as downregulation of vimentin expression by fluorescence analysis Induction of mesenchymal-epithelial transition in human SW-620 M-phenotype tumor organoid assessed as downregulation of vimentin expression by fluorescence analysis	[PMID: 35192363]

In Vitro

CHD1Li 6.11 shows an IC₅₀ of 2.6 μM against SW620 tumor organoid^[1].
CHD1Li 6.11 (1-100 μM, 24 h) reduces TCF-transcription in M-Phenotype SW620 and HCT116 cells^[1].
CHD1Li 6.11 (1-100 μM, 72 h) reduces viabilities in M-Phenotype SW620 and HCT116 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.

In Vivo

CHD1Li 6.11 (75-125 mg/kg, p.o., 5 times a week for 28 days) inhibits tumor growth in athymic nude mouse xenografts baring SW620 isolated M-Phenotype flank tumors^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Athymic nude mouse xenografts baring SW620 isolated M-Phenotype flank tumors^[1]
Dosage:

75 and 125 mg/kg
Administration:

Orally administration, 5 times a week for 28 days
Result:

Reduced tumor volume.
Had no abnormal observations associated with gross toxicity.

Chemical Information

CAS. Nr. 2716890-91-2
Appearance Solid
Molecular Weight 472.40
Formel C₂₁H₂₂BrN₅OS
Color Off-white to gray
SMILES

O=C(NC1=CC=C(NC2=NC(N3CCCC3)=NC(C)=C2)C=C1)CC4=CC(Br)=CS4
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (211.69 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.1169 mL

10.5843 mL

21.1685 mL

5 mM

0.4234 mL

2.1169 mL

4.2337 mL

10 mM

0.2117 mL

1.0584 mL

2.1169 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (5.29 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protokoll

All Molecular Biology Cell Biology Signal Pathway Related

Protocol for Electrophoretic Mobility Shift Assay (EMSA)
Electrophoretic mobility shift assay detects protein-nucleic acid binding by incubating a labeled DNA or RNA probe with purified protein or cell extract, then separating free probe from slower-migrating protein-probe complexes on a native gel. For cancer cells, primary neurons, mouse tumor samples, intestinal organoids, inflammatory macrophages, or drug-treated samples, EMSA can measure transcription-factor DNA binding or RNA-binding protein activity in extracts, but it does not directly measure transcription, protein expression, or chromatin occupancy in intact cells. Specificity is judged by competition with unlabeled wild-type probe, failure of mutated or unrelated competitors to compete, and antibody supershift or disruption when the binding protein identity must be confirmed.
Baculovirus-insect cell protein expression and purification
Baculovirus-insect cell expression uses recombinant baculovirus to deliver a target gene into insect cells, where late or very-late viral transcription drives recombinant protein production; the method was classically demonstrated by expression of human β-interferon in baculovirus-infected insect cells. The readout is target protein accumulation, assessed by activity, fluorescence if a fluorescent reporter is used, SDS-PAGE, Western blot, or purified protein yield. The system can express soluble, secreted, membrane-associated, and multiprotein targets, but expression outcome depends on the construct, baculovirus vector, insect cell line, multiplicity of infection, infection cell density, harvest time, and target-specific stability.
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
Patient-Derived Organoid (PDO) Establishment and Expansion
Patient-derived organoids (PDOs) are 3D in vitro models derived from patient tumor tissues that recapitulate the histological, genetic, and functional heterogeneity of the original tumors. These models are established by isolating tumor cells or tissue fragments and culturing them in a 3D extracellular matrix (ECM), such as Matrigel or decellularized ECM, to support self-organization, proliferation, and differentiation. The culture system preserves key features of the tumor microenvironment, including cell-cell interactions, stromal components, and ECM signaling, enabling accurate modeling of tumor biology and drug response for personalized medicine applications.
E. coli fusion-tag soluble protein purification
The purification of soluble recombinant proteins in Escherichia coli is achieved by fusing the target protein with a solubility-enhancing affinity tag (e. g. , His-tag, GST, MBP, Fh8, CSQ-tag, or thioredoxin) to improve expression yield, prevent aggregation, and enable efficient purification via affinity chromatography. The fusion protein is expressed under inducible promoters (e. g. , IPTG-induced T7 promoter), lysed from bacterial cells, and purified using resin-based affinity chromatography (e. g. , Ni-NTA for His-tag, amylose resin for MBP, chitin resin for intein tags, or HIC for Fh8). Tags can be removed post-purification using site-specific proteases (e. g. , TEV, enterokinase) or through intracellular cleavage systems. Solubility screening using multiple fusion partners (e. g. , Expresso® system) allows optimization of expression conditions for difficult-to-express proteins.
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
Inclusion-body expression, solubilization, refolding and purification
Inclusion-body recovery uses insoluble recombinant protein aggregates from E. coli as a starting material; the workflow is cell disruption, inclusion-body isolation/washing, denaturant or mild solubilization, refolding into soluble protein, and final chromatographic purification. The readouts are soluble protein recovery, purity by SDS-PAGE/chromatography, structural recovery by methods such as circular dichroism when used, and biological activity when an assay is available.
Protocol For Protein Expression And Purification
Recombinant protein expression in Escherichia coli followed by purification of a His-tagged soluble protein by immobilized metal affinity chromatography (IMAC), with optional MBP fusion and TEV tag removal when the construct includes these elements. The biological readout is production of the encoded target protein, detected as an inducible band at the expected molecular mass by SDS-PAGE and quantified by total protein assay or chromatographic absorbance; the purification readout is enrichment of the target protein in elution fractions after selective binding of polyhistidine residues to immobilized Ni2+/metal-chelate resin and elution by imidazole-containing buffer. Expression is driven by an inducible bacterial expression system, commonly T7/lac-based, in which IPTG or lactose/auto-induction activates transcription and translation of the cloned gene; lower induction temperature, lower inducer concentration, induction timing, and solubility-enhancing fusion tags can influence the frac
Mammalian transient protein expression and purification
Mammalian transient protein expression introduces plasmid DNA into HEK293 or CHO cells for short-term recombinant protein production, allowing secreted, glycosylated, Fc-tagged, His-tagged, or membrane proteins to be produced without stable clone generation.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (271 KB)
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Prigaro BJ, et al. Design, Synthesis, and Biological Evaluation of the First Inhibitors of Oncogenic CHD1L. J Med Chem. 2022;65(5):3943-3961. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.1169 mL	10.5843 mL	21.1685 mL	52.9213 mL
	5 mM	0.4234 mL	2.1169 mL	4.2337 mL	10.5843 mL
	10 mM	0.2117 mL	1.0584 mL	2.1169 mL	5.2921 mL
	15 mM	0.1411 mL	0.7056 mL	1.4112 mL	3.5281 mL
	20 mM	0.1058 mL	0.5292 mL	1.0584 mL	2.6461 mL
	25 mM	0.0847 mL	0.4234 mL	0.8467 mL	2.1169 mL
	30 mM	0.0706 mL	0.3528 mL	0.7056 mL	1.7640 mL
	40 mM	0.0529 mL	0.2646 mL	0.5292 mL	1.3230 mL
	50 mM	0.0423 mL	0.2117 mL	0.4234 mL	1.0584 mL
	60 mM	0.0353 mL	0.1764 mL	0.3528 mL	0.8820 mL
	80 mM	0.0265 mL	0.1323 mL	0.2646 mL	0.6615 mL
	100 mM	0.0212 mL	0.1058 mL	0.2117 mL	0.5292 mL

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

CHD1Li 6.11

Alle DNA/RNA Synthesis Isoform-spezifische Produkte anzeigen